We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FMC's Q4 Earnings and Revenues Miss Estimates on Lower Prices
Read MoreHide Full Article
Key Takeaways
FMC reported a Q4 loss, with revenues down 11.5% Y/Y and adjusted EPS falling to $1.20.
FMC sales fell due to price declines led by Rynaxypyr, while Latin America competition hurt volumes.
FMC guided Q1 revenues of $725-$775M and sees FY revenues down about 5% Y/Y.
FMC Corporation (FMC - Free Report) reported a loss of $13.74 per share for the fourth quarter of 2025. This was wider compared to the loss of 13 cents in the year-ago quarter.
Barring one-time items, adjusted earnings per share (EPS) were $1.20, down from $1.79 reported a year ago. It missed the Zacks Consensus Estimate of $1.21.
Revenues were $1,083.3 million in the quarter, down around 11.5% from the year-ago quarter’s levels. It also lagged the Zacks Consensus Estimate of $1,150 million.
Fourth-quarter revenues decreased primarily due to a steep price decline, mainly in Rynaxypyr. The competition was also intense for core products, especially in Latin America, leading to stunted volumes.
In North America, sales increased 3% year over year to $350.5 million in the quarter. Sales in North America increased as a result of higher volumes driven by herbicides and fungicides, and strong growth of fluindapyr. Sales topped the consensus estimate of $346.7 million.
Latin American sales saw a 5% year-over-year decrease to $371.1 million in the reported quarter. Sales in Latin America suffered from increased pressure from generics, leading to lower volumes and price declines of branded products. It missed the consensus estimate of $416.3 million.
In Asia, excluding India, revenues declined 41.1% from the previous year to $180.7 million. Sales declined due to lower volumes driven by weather and the price declines of the branded products. It missed the consensus estimate of $186.3 million.
EMEA experienced a 2% year-over-year sales decrease to $183.8 million in the reported quarter. The downside was primarily due to lower volumes from adverse weather and weak grower economics. It lagged the consensus estimate of $196.9 million.
FMC’s Financials
The company had cash and cash equivalents of $584.5 million at the end of the quarter. Long-term debt was $2,769.8 million.
FMC’s Q1 and FY 2026 Guidance
FMC expects first-quarter revenues to range between $725 million and $775 million, implying a 5% decline at the midpoint compared to 2025. Adjusted EBITDA is forecasted between $45 million and $55 million, indicating a 58% decline at the midpoint. Adjusted loss per share is projected to be 32 cents to 44 cents, indicating a 56-cent year-over-year decrease at the midpoint.
Additionally, full-year revenues are expected to range between $3.60 billion and $3.80 billion, implying a 5% decline at the midpoint compared to the previous year. Adjusted EBITDA is expected to be $670-$730 million, indicating a decline of 17% at the midpoint compared to the prior year. Adjusted EPS is expected to be between $1.63 and $1.89, calling for a year-on-year decrease of 41% at the midpoint.
FMC also announced its strategic priorities for 2026 and its board’s authorization to explore strategic options, including, but not limited to, the sale of the company.
FMC’s Price Performance
FMC’s shares have plunged 52.3% in the past year against the industry’s 15.4% growth.
Image Source: Zacks Investment Research
FMC’s Zacks Rank & Key Picks
FMC currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks worth a look in the basic materials space include Albemarle Corporation (ALB - Free Report) , Coeur Mining, Inc. (CDE - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .
Albemarle is slated to report fourth-quarter results on Feb. 11. The Zacks Consensus Estimate for earnings is pegged at a loss of 53 cents. ALB beat the Zacks Consensus Estimate in three of the last four quarters while missing once, with the average earnings surprise being 35.28%. ALB sports a Zacks Rank #1 (Strong Buy) at present. You can seethe complete list of today’s Zacks #1 Rank stocks here.
Coeur is scheduled to report fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for CDE’s fourth-quarter earnings is pegged at 33 cents. CDE beat the Zacks Consensus Estimate in three of the last four quarters and missed once, with the average earnings surprise being 106.61%. CDE currently sports a Zacks Rank #1.
Avino Silver is slated to report fourth-quarter results on March 11. The consensus estimate for ASM’s earnings is pegged at 6 cents. ASM, carrying a Zacks Rank #2 (Buy), beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 150%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FMC's Q4 Earnings and Revenues Miss Estimates on Lower Prices
Key Takeaways
FMC Corporation (FMC - Free Report) reported a loss of $13.74 per share for the fourth quarter of 2025. This was wider compared to the loss of 13 cents in the year-ago quarter.
Barring one-time items, adjusted earnings per share (EPS) were $1.20, down from $1.79 reported a year ago. It missed the Zacks Consensus Estimate of $1.21.
Revenues were $1,083.3 million in the quarter, down around 11.5% from the year-ago quarter’s levels. It also lagged the Zacks Consensus Estimate of $1,150 million.
Fourth-quarter revenues decreased primarily due to a steep price decline, mainly in Rynaxypyr. The competition was also intense for core products, especially in Latin America, leading to stunted volumes.
FMC Corporation Price, Consensus and EPS Surprise
FMC Corporation price-consensus-eps-surprise-chart | FMC Corporation Quote
FMC’s Regional Sales Performance
In North America, sales increased 3% year over year to $350.5 million in the quarter. Sales in North America increased as a result of higher volumes driven by herbicides and fungicides, and strong growth of fluindapyr. Sales topped the consensus estimate of $346.7 million.
Latin American sales saw a 5% year-over-year decrease to $371.1 million in the reported quarter. Sales in Latin America suffered from increased pressure from generics, leading to lower volumes and price declines of branded products. It missed the consensus estimate of $416.3 million.
In Asia, excluding India, revenues declined 41.1% from the previous year to $180.7 million. Sales declined due to lower volumes driven by weather and the price declines of the branded products. It missed the consensus estimate of $186.3 million.
EMEA experienced a 2% year-over-year sales decrease to $183.8 million in the reported quarter. The downside was primarily due to lower volumes from adverse weather and weak grower economics. It lagged the consensus estimate of $196.9 million.
FMC’s Financials
The company had cash and cash equivalents of $584.5 million at the end of the quarter. Long-term debt was $2,769.8 million.
FMC’s Q1 and FY 2026 Guidance
FMC expects first-quarter revenues to range between $725 million and $775 million, implying a 5% decline at the midpoint compared to 2025. Adjusted EBITDA is forecasted between $45 million and $55 million, indicating a 58% decline at the midpoint. Adjusted loss per share is projected to be 32 cents to 44 cents, indicating a 56-cent year-over-year decrease at the midpoint.
Additionally, full-year revenues are expected to range between $3.60 billion and $3.80 billion, implying a 5% decline at the midpoint compared to the previous year. Adjusted EBITDA is expected to be $670-$730 million, indicating a decline of 17% at the midpoint compared to the prior year. Adjusted EPS is expected to be between $1.63 and $1.89, calling for a year-on-year decrease of 41% at the midpoint.
FMC also announced its strategic priorities for 2026 and its board’s authorization to explore strategic options, including, but not limited to, the sale of the company.
FMC’s Price Performance
FMC’s shares have plunged 52.3% in the past year against the industry’s 15.4% growth.
Image Source: Zacks Investment Research
FMC’s Zacks Rank & Key Picks
FMC currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks worth a look in the basic materials space include Albemarle Corporation (ALB - Free Report) , Coeur Mining, Inc. (CDE - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .
Albemarle is slated to report fourth-quarter results on Feb. 11. The Zacks Consensus Estimate for earnings is pegged at a loss of 53 cents. ALB beat the Zacks Consensus Estimate in three of the last four quarters while missing once, with the average earnings surprise being 35.28%. ALB sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Coeur is scheduled to report fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for CDE’s fourth-quarter earnings is pegged at 33 cents. CDE beat the Zacks Consensus Estimate in three of the last four quarters and missed once, with the average earnings surprise being 106.61%. CDE currently sports a Zacks Rank #1.
Avino Silver is slated to report fourth-quarter results on March 11. The consensus estimate for ASM’s earnings is pegged at 6 cents. ASM, carrying a Zacks Rank #2 (Buy), beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 150%.